Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

A new model aims to predict stillbirth before it happens

NCT ID NCT07745101

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This study is developing a prediction model to identify pregnancies at increased risk of stillbirth or fetal growth restriction, often caused by placental problems. Researchers will follow 7,000 pregnant individuals, collecting data from early pregnancy through delivery and postpartum. The goal is to use clinical information, biomarkers, and placental examinations to create a risk score that could guide care and potentially prevent stillbirth.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
No drug or device; this is an observational study developing a risk prediction model using clinical data, biomarkers, and placental pathology.
What this could lead to
If successful, this could lead to a tool that identifies high-risk pregnancies early, allowing closer monitoring and interventions to prevent stillbirth.
What could go wrong
The prediction model may not be accurate enough for widespread use, and the study's findings might not apply to all populations. It is observational, so it cannot prove that any intervention reduces stillbirth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 7,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jul 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population for the primary objective will include pregnant individuals who are screened and enrolled between 12.0 and 13.6 weeks of gestation at participating clinical sites ("Early Pregnancy Cohort"). Individuals may also be screened and enrolled at later gestational ages greater than or equal to 28 weeks gestation to address the secondary objectives of the project, including DFM, and FGR and relationship to perinatal nutrition and allostatic load ("Late Pregnancy Cohort"). This study will collect discarded neonatal cord blood post-delivery and will request access to neonatal medical record charts using appropriate HIPAA Authorization. We will also collect paternal saliva samples, when possible, after obtaining consent from the father.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Early Pregnancy Cohort Inclusion Criteria * 18 years of age * Gestational age at enrollment: Between 12.0 and 13.6 weeks of gestation * Pregnant individuals receiving care at participating clinical sites with intent of delivering at study hospital * Consent to participate in study procedures through 6 weeks postpartum Late Pregnancy Cohort * 18 years or older * Gestational age at enrollment: greater than or equal to 28.0 weeks gestational age * Clinical indications of risk FGR \<10th percentile or report of decreased fetal movement) * Pregnant individual receiving care at participating clinical sites with intent of delivering at study hospital * Consent to participate in study procedures through 6 weeks postpartum Exclusion Criteria: * Evidence of fetal genetic anomaly or major structural malformation * Known fetal aneuploidy based on chorionic villus sampling * Positive cell-free fetal DNA screening for aneuploidy * Multifetal gestation * Less than 18 years of age * Not fluent in either English or Spanish

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stillbirth are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Old Dominion University

    Norfolk, Virginia, 23529, United States

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

  • The Collaborative Action for Research to End Stillbirth (CARES) Research Center at Columbia University

    New York, New York, 10027, United States

  • University of California Center for Stillbirth Prevention

    San Diego, California, 92093, United States

  • University of Utah

    Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.